Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: A scientific study

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Kitada, Shuichi ^a,b   Otsuka, Yoritaka ^a,c   Kokubu, Nobuaki ^a   Kasahara, Yoichiro ^a   Kataoka, Yu ^a   Noguchi, Teruo ^a   Goto, Yoichi ^a   Kimura, Genjirou ^b   Nonogi, Hiroshi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c FUKUOKA WAJIRO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; STATIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; MAJOR ADVERSE CARDIOVASCULAR EVENT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; BLOOD; DISEASE FREE SURVIVAL; DISORDERS OF CARBOHYDRATE METABOLISM; GLUCOSE TOLERANCE TEST; HEART DISEASE; HEART INFARCTION; JAPAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME;

AGED; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; FEMALE; GLUCOSE METABOLISM DISORDERS; GLUCOSE TOLERANCE TEST; HEART DISEASES; HUMANS; HYPERGLYCEMIA; JAPAN; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 78149326477     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-75     Document Type: Article

References (41)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444. 10.2337/diacare.16.2.434, 8432214.
2. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996, 347:949-950. 10.1016/S0140-6736(96)91420-8, 8598762.
3. Schernthaner G. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract 1996, 31(Suppl):S3-13. 10.1016/0168-8227(96)01224-7, 8864635.
4. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48:937-942. 10.2337/diabetes.48.5.937, 10331395.
5. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes 1996, 45(Suppl 3):S14-16.
6. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924. 10.2337/diacare.22.6.920, 10372242.
7. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354:617-621. 10.1016/S0140-6736(98)12131-1, 10466661, Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology.
8. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, Tenerz A, Ohrvik J, Ryden L. Abnormal glucose tolerance--a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004, 256:288-297. 10.1111/j.1365-2796.2004.01371.x, 15367171.
9. Hashimoto K, Ikewaki K, Yagi H, Nagasawa H, Imamoto S, Shibata T, Mochizuki S. Glucose intolerance is common in Japanese patients with acute coronary syndrome who were not previously diagnosed with diabetes. Diabetes Care 2005, 28:1182-1186. 10.2337/diacare.28.5.1182, 15855586.
10. Ramachandran A, Chamukuttan S, Immaneni S, Shanmugam RM, Vishnu N, Viswanathan V, Jaakko T. High incidence of glucose intolerance in Asian-Indian subjects with acute coronary syndrome. Diabetes Care 2005, 28:2492-2496. 10.2337/diacare.28.10.2492, 16186285.
11. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359:2140-2144. 10.1016/S0140-6736(02)09089-X, 12090978.
12. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004, 25:1990-1997. 10.1016/j.ehj.2004.09.021, 15541834.
13. Tamita K, Katayama M, Takagi T, Akasaka T, Yamamuro A, Kaji S, Morioka S, Kihara Y. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J 2007, 71:834-841. 10.1253/circj.71.834, 17526977.
14. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197.
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S, 9686693.
16. Lenzen M, Ryden L, Ohrvik J, Bartnik M, Malmberg K, Scholte Op Reimer W, Simoons ML. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006, 27:2969-2974. 10.1093/eurheartj/ehl363, 17090612.
17. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. 10.1136/bmj.324.7329.71, 64503, 11786451.
18. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003, 108:1682-1687. 10.1161/01.CIR.0000091201.39590.CB, 14504182.
19. Metoprolol in acute myocardial infarction (MIAMI) A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 1985, 6:199-226. Metoprolol in acute myocardial infarction (MIAMI).
20. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986, 2:57-66. 10.1016/S0140-6736(02)92899-0, 2873379.
21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153. 10.1056/NEJM200001203420301, 10639539.
22. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788. 10.1016/S0140-6736(03)14974-4, 13678872.
23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
24. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009. 10.1056/NEJM199610033351401, 8801446.
25. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349-1357. 10.1056/NEJM199811053391902, 9841303.
26. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000, 16:125-132. 10.1002/(SICI)1520-7560(200003/04)16:2<125::AID-DMRR90>3.0.CO;2-4, 10751752.
27. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000, 130:963-974. 10.1038/sj.bjp.0703393, 1572156, 10882379.
28. Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M. Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia 2002, 45:151. 10.1007/s125-002-8256-1, 11845235.
29. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009, 8:23. 10.1186/1475-2840-8-23, 2688503, 19402896.
30. Knudsen EC, Seljeflot I, Michael A, Eritsland J, Mangschau A, Müller C, Arnesen H, Andersen G. Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study. Cardiovasc Diabetol 2010, 9:47. 10.1186/1475-2840-9-47, 2940874, 20809989.
31. Wallander M, Malmberg K, Norhammar A, Rydén L, Tenerz A. Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study. Diabetes Care 2008, 31:36-8. 10.2337/dc07-1552, 17909086.
32. Bartnik M, Rydén L, Malmberg K, Ohrvik J, Pyörälä K, Standl E, Ferrari R, Simoons M, Soler-Soler J, . Euro Heart Survey Investigators Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 2007, 93:72-7. 10.1136/hrt.2005.086975, 1861359, 16905628, Euro Heart Survey Investigators.
33. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M, Standl E, Soler-Soler J, Ohrvik J. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004, 25:1880-1890. 10.1016/j.ehj.2004.07.027, 15522466.
34. Hu DY, Pan CY, Yu JM, . China Heart Survey Group The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 2006, 27:2573-9. 10.1093/eurheartj/ehl207, 16984927, China Heart Survey Group.
35. Sourij H, Saely CH, Schmid F, Zweiker R, Marte T, Wascher TC, Drexel H. Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. Eur Heart J 2010, 31:1583-90. 10.1093/eurheartj/ehq099, 20436047.
36. Feinberg MS, Schwartz R, Tanne D, Fisman EZ, Hod H, Zahger D, Schwammethal E, Eldar M, Behar S, Tenenbaum A. Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol 2007, 99:667-72. 10.1016/j.amjcard.2006.10.023, 17317369.
37. Fisman EZ, Motro M, Tenenbaum A, Boyko V, Mandelzweig L, Behar S. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J 2001, 141:485-90. 10.1067/mhj.2001.113219, 11231448.
38. Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008, 29:177-184. 10.1093/eurheartj/ehm519, 18156611.
39. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289. 10.1016/S0140-6736(05)67528-9, 16214598.
40. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494. 10.1001/jama.290.4.486, 12876091.
41. Kragelund C, Snorgaard O, Køber L, Bengtsson B, Ottesen M, Højberg S, Olesen C, Kjaergaard JJ, Carlsen J, Torp-Petersen C, . TRACE Study Group Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients. Eur Heart J 2004, 25:1891-7. 10.1016/j.ehj.2004.07.033, 15522467, TRACE Study Group.